JW Shinyak, a subsidiary of JW Holdings, said on Thursday that it has launched Unitok, an oral hand eczema treatment.

The drug, which uses alitretinoin as its main ingredient, indicates to treat recurrent chronic severe hand eczema in adults who do not respond to at least four weeks of potent topical steroid therapy. The treatment is also a vitamin A derivative that suppresses inflammation and regulates immune function

Other benefits of Unitok include improved convenience with patients having only to take one capsule a day and reduced financial burden as it is cheaper than existing products.

“Unitok can reduce pain in patients with chronic hand eczema that has been difficult to treat with topical steroids,” a company official said in a press release. “The company will continue to introduce therapeutic products that can improve the quality of life of patients.”

As Unitok is an ethical drug (ETC), patients wishing to buy the medicine can do so after consulting with their doctors.